Editorial
Treatment of resectable stage IIIA non-small cell lung cancer
Abstract
Surgical treatment of stage IIIA non-small cell lung cancer (NSCLC) remains a controversial area in the management of lung cancer despite being considered as part of combined modality therapy over the last two decades (1).
